Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome.
Ki-67
apparent diffusion coefficient
diffusion-weighted imaging
magnetic resonance imaging
patients living with HIV
primary central nervous system lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Oct 2019
08 Oct 2019
Historique:
received:
01
08
2019
revised:
27
09
2019
accepted:
02
10
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
The ability to non-invasively predict outcomes and monitor treatment response in primary central nervous system lymphoma (PCNSL) is important as treatment regimens are constantly being trialed. The aim of this study was to assess the validity of using apparent diffusion coefficient (ADC) histogram values to predict Ki-67 expression, a tumor proliferation marker, and patient outcomes in PCNSL in both immunocompetent patients and patients living with HIV (PLWH). Qualitative PCNSL magnetic resonance imaging (MRI) characteristics from 93 patients (23 PLWH and 70 immunocompetent) were analyzed, and whole tumor segmentation was performed on the ADC maps. Quantitative histogram analyses of the segmentations were calculated. These measures were compared to PCNSL Ki-67 expression. Progression-free survival (PFS) and overall survival (OS) were analyzed via comparison to the International Primary Central Nervous System Lymphoma Collaboration Group Response Criteria. Associations between ADC measures and clinical outcomes were assessed using univariate and multivariate Cox proportional hazards models. Normalized ADC (nADC)
Identifiants
pubmed: 31597366
pii: cancers11101506
doi: 10.3390/cancers11101506
pmc: PMC6827036
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Radiology. 2013 Aug;268(2):318-22
pubmed: 23882093
Neuroradiology. 2001 Jan;43(1):29-35
pubmed: 11214644
Clin Radiol. 2016 Oct;71(10):1018-29
pubmed: 27341986
Appl Immunohistochem Mol Morphol. 2018 Apr;26(4):254-262
pubmed: 27490760
Oncol Lett. 2017 Nov;14(5):5505-5512
pubmed: 29113178
Neoplasia. 2009 Feb;11(2):102-25
pubmed: 19186405
AJNR Am J Neuroradiol. 2005 Feb;26(2):236-41
pubmed: 15709118
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1601-1618
pubmed: 29200113
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Medicine (Baltimore). 2017 Jan;96(3):e5910
pubmed: 28099354
Clin Cancer Res. 2012 Feb 15;18(4):1146-55
pubmed: 22228634
Acta Neuropathol. 2014 Feb;127(2):175-88
pubmed: 24240734
J Clin Oncol. 2005 Aug 1;23(22):5034-43
pubmed: 15955902
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):984-92
pubmed: 20616176
AJNR Am J Neuroradiol. 2013 Jan;34(1):35-40
pubmed: 22936096
Diagn Pathol. 2016 Aug 30;11(1):82
pubmed: 27576949
AJNR Am J Neuroradiol. 2010 Jan;31(1):60-6
pubmed: 19729544
Acta Haematol. 2011;126(1):44-51
pubmed: 21430371
Am J Clin Oncol. 2015 Apr;38(2):140-6
pubmed: 23608829
PLoS One. 2014 Nov 13;9(11):e112948
pubmed: 25393543
PLoS One. 2016 Aug 29;11(8):e0161386
pubmed: 27571268
J Neuroimaging. 2008 Oct;18(4):411-7
pubmed: 18494774
Neurosurg Focus. 2006 Nov 15;21(5):E4
pubmed: 17134120
Curr Hematol Malig Rep. 2014 Sep;9(3):243-53
pubmed: 24969265
Radiology. 2002 Jul;224(1):177-83
pubmed: 12091680
Clin Radiol. 2015 Aug;70(8):909-16
pubmed: 26050534
Transl Oncol. 2018 Apr;11(2):504-510
pubmed: 29522972
Clin Radiol. 2011 Aug;66(8):768-77
pubmed: 21513925
Oncotarget. 2017 May 10;8(35):59492-59499
pubmed: 28938652
Neuro Endocrinol Lett. 2016 Sep;37(4):318-324
pubmed: 27857050
Oncotarget. 2017 Aug 24;8(43):75434-75444
pubmed: 29088879
Cancer Causes Control. 2019 May;30(5):477-488
pubmed: 30888569
J Neurooncol. 2011 Jan;101(2):257-65
pubmed: 20526793
Hematol Oncol. 2014 Jun;32(2):57-67
pubmed: 23949943
AJNR Am J Neuroradiol. 2016 Nov;37(11):2010-2018
pubmed: 27390318